title: Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma.
abstract: We previously reported that in vitro hypoxic condition enhanced VEGF level and its receptor expression in hepatic cancer cell line, HepG2. Transcatheter hepatic arterial embolization (TAE) therapy is one of the vasculo-occlusive and hypoxic challenges to hepatocellular carcinoma (HCC). Therefore, we examined the level of VEGF in sera of patients with HCC who underwent TAE during the course of the treatment. Thirty-eight patients with HCC and hepatitis C virus-positive cirrhosis were studied. Peripheral blood samples were taken before and 1, 3 and 7 days after TAE with informed consent. The serum levels of VEGF as well as hepatocyte growth factor (HGF), another hepatic remodeling factor, were measured. The molar ratio (BTR) of serum branched chain amino acid (BCAA) to tyrosine (Tyr), the serum levels of AST, ALT and LDH were also examined. Although the level of AST, ALT and LDH reached the peak value within 1 day after TAE, VEGF level increased significantly 7 days later. On the other hand, there were no significant alterations in the levels of HGF and BTR during the course of TAE. Although the level of HGF was significantly correlated with the level of VEGF before TAE, this correlation was no more observed after TAE. These data collectively suggest that VEGF may be secreted in response to clinical hypoxic intervention, TAE, independent of HGF or altered amino acid metabolism. VEGF may play a role as a sensitive marker for tumor ischemia.
authors.affiliation: Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: C
authors.initials: C
authors.lastname: Kawaguchi
authors.forename: M
authors.initials: M
authors.lastname: Adachi
authors.forename: S
authors.initials: S
authors.lastname: Miura
authors.forename: H
authors.initials: H
authors.lastname: Ishii
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000201:enzymology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D016228:Endothelial Growth Factors / Q000097:blood*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000628:therapy; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D008103:Liver Cirrhosis / Q000097:blood / Q000628:therapy / Q000821:virology; D008113:Liver Neoplasms / Q000097:blood* / Q000201:enzymology / Q000628:therapy*; D008222:Lymphokines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D015251:Epirubicin; D007459:Iodized Oil